BioMarin Pharmaceutical (BMRN) Competitors

BioMarin Pharmaceutical logo
$65.86 +2.31 (+3.63%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$64.59 -1.27 (-1.92%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXAS, EXEL, RGEN, MDGL, and HALO

Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry.

BioMarin Pharmaceutical vs.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.

BioMarin Pharmaceutical received 427 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.55% of users gave BioMarin Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
Alnylam PharmaceuticalsOutperform Votes
1140
76.20%
Underperform Votes
356
23.80%
BioMarin PharmaceuticalOutperform Votes
1567
74.55%
Underperform Votes
535
25.45%

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

BioMarin Pharmaceutical has a net margin of 11.71% compared to Alnylam Pharmaceuticals' net margin of -15.86%. BioMarin Pharmaceutical's return on equity of 8.53% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-15.86% N/A -8.38%
BioMarin Pharmaceutical 11.71%8.53%6.40%

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 15 mentions for BioMarin Pharmaceutical and 12 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.95 beat Alnylam Pharmaceuticals' score of 0.65 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
10 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals currently has a consensus target price of $298.61, indicating a potential upside of 12.28%. BioMarin Pharmaceutical has a consensus target price of $94.20, indicating a potential upside of 43.03%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.72
BioMarin Pharmaceutical
0 Sell rating(s)
7 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.74

BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$1.83B18.76-$440.24M-$2.62-101.51
BioMarin Pharmaceutical$2.42B5.19$167.65M$1.6739.44

Summary

BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 14 of the 18 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRN vs. The Competition

MetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.26B$7.02B$5.78B$9.16B
Dividend YieldN/A2.91%5.32%4.00%
P/E Ratio39.444.0155.9614.33
Price / Sales5.19312.26984.6373.99
Price / Cash35.9675.4646.0938.87
Price / Book2.515.535.125.00
Net Income$167.65M$123.50M$113.24M$222.75M
7 Day Performance2.36%-3.29%-1.43%-1.01%
1 Month Performance-1.69%-0.08%4.81%4.04%
1 Year Performance-23.53%5.40%25.30%21.71%

BioMarin Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRN
BioMarin Pharmaceutical
4.9124 of 5 stars
$65.86
+3.6%
$94.20
+43.0%
-25.3%$12.26B$2.42B39.443,401Analyst Upgrade
News Coverage
ALNY
Alnylam Pharmaceuticals
4.4597 of 5 stars
$273.67
-0.9%
$298.61
+9.1%
+57.1%$35.30B$2.09B-104.452,100Analyst Forecast
Short Interest ↓
BIIB
Biogen
4.7243 of 5 stars
$142.50
+0.8%
$228.80
+60.6%
-45.5%$20.77B$9.61B12.877,570Earnings Report
Analyst Forecast
Options Volume
News Coverage
UTHR
United Therapeutics
4.463 of 5 stars
$345.38
-0.7%
$382.08
+10.6%
+71.4%$15.42B$2.76B15.171,168Insider Trade
Analyst Revision
INCY
Incyte
4.5136 of 5 stars
$68.30
-7.9%
$75.71
+10.8%
+19.4%$13.16B$3.70B487.892,524Earnings Report
Analyst Forecast
Short Interest ↑
NBIX
Neurocrine Biosciences
4.9589 of 5 stars
$118.80
-3.1%
$168.35
+41.7%
-10.2%$12.03B$2.36B36.111,400Earnings Report
Analyst Forecast
Insider Trade
Short Interest ↓
EXAS
Exact Sciences
4.7968 of 5 stars
$52.34
-2.2%
$72.76
+39.0%
-18.9%$9.69B$2.69B-44.736,600Upcoming Earnings
Positive News
EXEL
Exelixis
4.9339 of 5 stars
$33.50
+0.1%
$36.06
+7.7%
+60.9%$9.57B$1.83B21.471,310Earnings Report
Analyst Downgrade
Short Interest ↓
Analyst Revision
News Coverage
RGEN
Repligen
4.1975 of 5 stars
$153.94
-1.4%
$186.00
+20.8%
-29.2%$8.63B$638.76M-416.041,783Analyst Forecast
News Coverage
Positive News
MDGL
Madrigal Pharmaceuticals
3.5819 of 5 stars
$337.57
+1.5%
$351.67
+4.2%
+57.2%$7.36B$76.81M-13.4690Analyst Revision
HALO
Halozyme Therapeutics
4.3721 of 5 stars
$57.34
+0.4%
$60.89
+6.2%
+62.8%$7.29B$947.36M18.99390Upcoming Earnings
Analyst Revision

Related Companies and Tools


This page (NASDAQ:BMRN) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners